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Running title: MASP-1 plays a role in alternative pathway activation 
 
Abstract 
The complement system is a sophisticated network of proteases. Here, we describe an 
unexpected link between two “linear” activation routes of the complement system: the lectin 
(LP) and the alternative pathways (AP).  MASP-1 is known to be the initiator protease of the 
LP. Using a specific and potent inhibitor of MASP-1, SGMI-1, and also other MASP-1 
inhibitors with different mechanism of action, we demonstrated that in addition to its 
functions in the LP, MASP-1 is also essential for bacterial LPS-induced AP activation, while 
it has little effect on zymosan-induced AP activation. We have shown that MASP-1 inhibition 
does not only prevent AP activation, but it also attenuates an already initiated AP activity on 
LPS-surface. This newly recognized function of MASP-1 can be important for the defense 
against certain bacterial infections. Our results also emphasize that the mechanism of AP 
activation depends on the activator surface. 
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Introduction 
Complement is a proteolytic cascade, which can be activated via three different routes: the 
classical (CP), the lectin (LP) and the alternative pathways (AP). Ca2+-dependent complexes 
consisting of pattern recognition molecules (PRMs) and associated serine proteases initiate 
the CP and the LP. The most abundant protease of the LP is MASP-1. When the LP is 
triggered, MASP-1 autoactivates first, then it cleaves MASP-2 in normal human serum (NHS) 
(1). MASP-2 cleaves C4, while C2 is cleaved by both MASP-1 and MASP-2. The LP 
generates the same type of C3 convertase (C4b2a) as the CP. The mechanism of AP activation 
is quite different, since there is no known PRM of the AP. Properdin, the positive regulator of 
the AP, was suggested to act as a PRM, but this issue is controversial (2). AP is initiated when 
C3b or C3b-like molecules emerge near a surface. C3b can covalently bind to the surface and 
it binds factor B (FB). C3b bound FB is cleaved by factor D (FD), a serine protease that 
circulates predominantly in the active form. The resulting C3bBb is the AP C3 convertase, 
which converts more C3 into C3b providing a positive feedback. Properdin, the only known 
positive regulator of complement, stabilizes the AP C3 convertase (3). The AP can be 
initiated independently of the CP or the LP. According to the prevailing “tickover” 
hypothesis, the reactive thioester bond of C3 slowly hydrolyzes in the fluid phase, and the 
emerging C3b-like molecule, C3(H2O), binds FB. After having been cleaved by FD the 
resulting C3(H2O)Bb complex acts as a C3 convertase. If this fluid-phase convertase is 
generated near a surface, the nascent C3b molecules can bind there covalently and initiate the 
amplification process. Endogenous cells are protected from excessive complement activation 
by cell-surface-anchored and fluid-phase inhibitors. The most important AP inhibitor is factor 
H (FH), which can bind to self-surface-deposited C3b and destroy it by recruiting the serine 
protease, factor I (FI). 
The three activation pathways had been considered as independent activation routes, 
however, evidence has begun to accumulate suggesting various cross talks. Recently an 
important connection between the LP and the AP has been demonstrated. Activated MASP-3 
is a protease responsible for activating pro-FD in the circulation (4-6), and in fact it is the only 
protease doing so in resting human blood (7).  
Here, we describe an unexpected link between the LP and the AP demonstrating a 
novel function of MASP-1. On certain activator surfaces MASP-1 has been found to be 
indispensable for AP activation in the absence of Ca2+. This phenomenon might be of great 
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importance for the protection against invading microorganisms, but it also might contribute to 
uncontrolled complement activation leading to severe symptoms. 
 
Materials and methods 
Reagents 
All commonly used reagents were purchased from Sigma-Aldrich or Merck unless otherwise 
indicated. Human FB was purchased from Merck (Calbiochem brand). Human C1 inhibitor 
(Berinert P) was from CSL Behring. LPS from three different Gram-negative bacterial strains, 
such as Salmonella typhimurium (L6511), Escherichia coli (L8274) and Pseudomonas 
aeruginosa (L9143) was purchased from Sigma-Aldrich. Saccharomyces cerevisiae (sc-
258367A) Zymosan A was from Santa Cruz Biotechnology. 
Human serum, anti-MASP-1 antibody and purified proteins 
NHS collected from 10 healthy volunteers was pooled and stored at -80 °C. Production of 
antibody (αM1-SP) against the serine protease domain (SP) of MASP-1 is described in (6). 
MASP-1-depleted serum was prepared by running NHS through an anti-MASP-1 column 
(αM1-SP-Sepharose) twice. The catalytic fragment of human MASP-1 (rMASP-1cf) was 
purified as described (8). The N-terminal fragment of MASP-1 (M1_D1-3) was purified as 
described (9). MASP-1-specific inhibitor (SGMI-1) and MASP-2-specific inhibitor (SGMI-2) 
were produced as described (10). The MASP-3-specific inhibitor (TFMI-3) was prepared as 
described (7). Recombinant FD was produced as described (5). The recombinant serpin 
domain of human C1 inhibitor was produced as described (11). C3 was purified from human 
EDTA plasma (12). C3b was generated from C3 using trypsin (T8003, Sigma-Aldrich), which 
was later chromatographically removed from C3b. 
C3 deposition in Mg2+- EGTA buffer 
Microtiter plates were coated with 10 µg/ml mannan, 10 µg/ml LPS or 100 µg/ml zymosan in 
15 mM Na2CO3, 35 mM NaHCO3, pH 9.6. After overnight incubation at 4 °C, the wells were 
blocked with 1% BSA in TBS buffer (50 mM Tris, 150 mM NaCl, pH 7.4) for 1 h at 37 °C, 
then washed three times with 0.1 % Tween-20 in TBS buffer. NHS was diluted 6-fold in 10 
mM HEPES, 150 mM NaCl, 10 mM EGTA, 4 mM MgCl2, 0.1% Tween-20, pH 7.4 and if 
required it was pre-incubated in microcentrifuge tubes with inhibitors for 30 mins at 25 °C. 
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The samples were added to the microtiter plates and further incubated for 45 mins at 37 °C. 
The plates were washed; then 5000-fold diluted anti-human C3c (A0062, DakoCytomation) 
and 40 000-fold diluted anti-rabbit IgG HRP conjugate (A1949, Sigma-Aldrich) were applied 
in 1% BSA-wash buffer. Ortho-phenylene-diamine (OPD) in 50 mM citrate buffer (pH 5.0) 
was used for detection. The absorbance was read at 490 nm. 
FB cleavage assay 
1.23 µM C3b and 1.07 µM FB were incubated with or without recombinant FD (0.25 nM); or 
with recombinant FD (0.25 nM) and SGMI-1 (20.5 µM); or with rMASP-1cf (50 nM) in 100 
mM NaCl, 50 mM Tris-HCl, 5 mM MgCl2, 5 mM CaCl2, pH 7.4 at 37 °C. Samples were 
taken at 0 and 1.5 hours. Reactions were stopped by 2-fold dilution with SDS-PAGE sample 
buffer and heating for 3 mins at 95 °C. Samples were then analyzed by 10% SDS-PAGE 
under reducing conditions. 
 Inhibition assays 
The activity of the AP was measured in the presence of MASP-1-specific inhibitors (SGMI-
1), 1.25-20 µM; anti-MASP-1 antibody (αM1-SP), 2.1-133 nM; N-terminal fragment of 
MASP-1 (M1_D1-3), 0.06-7.3 µM; specific inhibitors of other complement proteases (SGMI-
2, 1.25-20 µM; TFMI-3, 0.29-30 µM); full length C1 inhibitor, 0.35-11.3 µM; and serpin 
domain of C1 inhibitor, 1.14-9.1 µM. The effect of the above-mentioned molecules was 
followed through the decrease in C3 deposition. 
Inhibition of ongoing C3 deposition 
6-fold diluted NHS was incubated in the separate wells of LPS-coated microtiter plates for 45 
mins at 37 °C. During this period at different time points same volume (4.8 µl) of SGMI-1 or 
FUT-175 inhibitors were added to the individual reactions to reach a final concentration of 20 
µM and 100 µM, respectively. Same volume of serum dilution buffer was also added to some 
wells as negative control. After a total of 45 mins serum was discarded, the microtiter plate 
was washed and the deposited C3 fragments were measured similarly as described above. 
Statistical analysis 
Statistical analysis was performed with Origin 6.0 (OriginLab Corporation, Northampton, 
Massachusetts) software. Student’s t-test was used to determine significant difference 
5 
 
between the control and treated samples. Two levels of significance were used: *p<0.05 and 
** p<5x10-9. 
 
Results and discussion 
MASP-1-specific inhibitor blocks AP activation on LPS-coated but not on zymosan-coated 
surface 
To reveal the individual roles of MASPs in complement activation we have previously 
developed selective and potent inhibitors against MASP-1 (SGMI-1), MASP-2 (SGMI-2) and 
MASP-3 (TFMI-3) (7, 10). In this study, we used these inhibitors to monitor activation of the 
AP using 6-fold diluted NHS in Mg2+-EGTA buffer. We set up ELISA assays for measuring 
C3 deposition. For measuring AP activation on plates two activators are used routinely: 
bacterial LPS and yeast zymosan. To our great surprise the MASP-1-specific inhibitor 
(SGMI-1), at a concentration of 10 µM, efficiently inhibited C3 deposition and caused near 
complete abrogation at 20 µM on LPS-coated surface (IC50=6.2 µM) (Fig. 1A). Contrary to 
that, only partial (~20%) inhibitory effect was detected on zymosan-coated surface even at the 
highest inhibitor concentration (20 µM) (Fig. 1A). SGMI-2, the MASP-2-specific inhibitor, 
caused only marginal inhibition of C3 deposition on LPS-coated surface and had no effect on 
zymosan-coated one (Fig. 1B).  Inhibition of MASP-3 using TFMI-3 did not influence either 
the LPS- or the zymosan-induced AP activation (Fig. 1C). These results imply that MASP-1 
has a key role in the AP activation on LPS-coated surface. The IC50 value for the inhibition of 
LPS-induced AP activation by SGMI-1 (6.2 µM) is much higher than the value (20 nM) 
calculated by considering only the 7 nM Kd value of the enzyme/inhibitor complex and the 
molar concentration of MASP-1 (25 nM) in the assay. We suggest that the complexity of the 
serum, and the multistep nature of the ELISA assay we used, results in an IC50 value 
significantly higher than expected. 
MASP-1 inhibitors having different mechanisms of action elicit the same effect on AP 
activation 
Since the inhibitory effect of SGMI-1 on AP activation was detected only at relatively high 
inhibitor concentration, we had to rule out the possibility, that the observed effect of SGMI-1 
is exerted through its weak, nonspecific inhibition of a protease or proteases other than 
MASP-1. To this end, we applied MASP-1 inhibitors having different mechanism of action. A 
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polyclonal antibody developed against the SP domain of human MASP-1 (αM1-SP) showed a 
concentration-dependent inhibitory effect on C3 deposition on LPS-coated surface, while it 
had only marginal effect on zymosan-coated surface (Fig. 2A). At 130 nM concentration, it 
completely prevented LPS-induced AP activation. This antibody is also an efficient LP 
inhibitor (Supplemental Fig. 1). 
The N-terminal fragment of MASP-1 is responsible for dimerization and for binding to the 
PRMs. Therefore, we investigated the effect of the N-terminal fragment of MASP-1 (M1_D1-
3) on the AP activity. It has already been shown that M1_D1-3 is able to attenuate LP 
activation in NHS through displacing the MASPs from the PRMs (9). M1_D1-3 behaved 
similarly to SGMI-1 in the AP assay system: it inhibited AP activation on the LPS-coated 
surface in a concentration dependent manner, whereas it showed only limited effect on the 
zymosan-coated plate (Fig. 2B). This result suggests that binding of MASP-1 via its N-
terminal region to a PRM or to other unknown molecules plays an important role in AP 
activation triggered by LPS. The binding molecule cannot be MBL, since MBL-binding to 
carbohydrates is strictly Ca2+-dependent. It is very likely that the PRM-MASPs complexes are 
largely intact at physiological salt concentration in the presence of Mg2+-EGTA (13, 14). We 
tried to demonstrate MASP-1-binding to LPS-coated wells using the MASP-1-specific 
antibody, but we could not detect any signal (data not shown). This could mean that the 
binding is weak or transient, but it is still enough to support AP activation on the LPS surface. 
It should be noted, that M1_D1-3 is not strictly MASP-1-specific: it displaces all MASPs and 
MAPs from the PRMs. 
The natural inhibitors of MASPs are serpins. C1 inhibitor is an efficient inhibitor of the LP in 
NHS (15). We tried to prevent MASP-1-mediated AP activation using C1 inhibitor. We did 
not get any inhibition of C3 deposition on LPS-coated plates using natural C1 inhibitor 
isolated from human blood (Fig. 2C). Contrary to that, we detected concentration dependent 
inhibition using the recombinant serpin domain of C1 inhibitor (Fig. 2C). C1 inhibitor is an 
atypical serpin, since besides of the serpin domain it possesses a heavily glycosylated N-
terminal domain as well. Our results indicate that in the LPS-induced AP-activation system 
the N-terminal domain somehow prevents the interaction between MASP-1 and C1 inhibitor. 
On the other hand, the single globular serpin domain of C1 inhibitor has a free access to 
active MASP-1 under these conditions. Similar observations were reported earlier using StcE-
treated C1 inhibitor. StcE is a metalloprotease secreted by E. coli O157:H7 that can remove 
the N-terminal domain of C1 inhibitor. The resulting truncated C1 inhibitor efficiently 
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inhibits endothelial cell-bound kallikrein, whereas the full-length C1 inhibitor fails to do so 
(16). This suggests that the N-terminal domain of C1 inhibitor might have an important 
regulatory function: it hinders the rapid and efficient interaction between the serpin and the 
target protease on a surface of a pathogen promoting complement activation, while the full-
length molecule can successfully prevent spontaneous activation of the complement proteases 
in the fluid phase. On the zymosan-coated surface neither the full-length C1 inhibitor nor the 
serpin domain could attenuate AP activation. Fig. 2D summarizes the results of 3 independent 
measurements with each inhibitor on LPS and zymosan surface.  
 To corroborate the results obtained by using various inhibitors in NHS, we checked 
the ability of MASP-1-depleted serum to activate the AP in our assay system. In accordance 
with the above results, the MASP-1-depleted serum showed very low AP activity on LPS-
coated surface, while the AP activity was only partially compromised on zymosan-coated 
surface (Fig. 3A). Taken together, these results show that MASP-1 has a central role in LPS-
induced AP activation. 
Surface dependence of the MASP-1-mediated AP activation 
To refine our knowledge about the surface requirement of MASP-1-mediated AP activation 
we tested various AP activators. Besides the LPS type (S. typhimurium) that we used in the 
experiments above, we checked LPS preparations from other bacteria as well. Both the E. coli 
and the P. aeruginosa LPS preparations gave the same results: high level C3 deposition that 
could be almost completely inhibited by 20 µM SGMI-1 (Fig. 3B). Selander et al. (17) 
demonstrated that mannan-coated surface induces efficient AP activation in Mg2+-EGTA 
buffer. Using the same activation surface, we showed that the mannan-induced AP activation 
can also be blocked by our MASP-1-specific inhibitor (Fig. 3B). Finally, we tested the lysis of 
rabbit erythrocytes, a frequently used method to measure AP activity. In this assay system 18-
fold diluted human serum readily lysed rabbit erythrocytes, and the lysis could not be 
attenuated by SGMI-1 even at high concentration (20 µM) (data not shown). Our results are in 
line with those of Degn et al. (18), who used MASP-1/3-deficient serum form a patient having 
3MC syndrome and measured efficient lysis of rabbit erythrocytes. 
Inhibition of MASP-1 attenuates C3 deposition in progress  
Theoretically, AP activation can be divided into distinct parts: the first part is the initiation lag 
phase, when the first few C3b molecules deposit on the activation surface, and the second part 
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is the amplification phase, when the surface deposited C3b molecules serve as a base for 
generating additional C3 convertase complexes building up the positive feed-back loop.  We 
also studied to which phase of the AP activation MASP-1 contributes. To this end we 
launched parallel AP activation experiments incubating NHS on LPS-coated surface for 
different time periods to let the C3b deposition reach a certain level, and then we added the 
same volume of SGMI-1 or FUT-175 or buffer to the individual reactions. FUT-175 is a 
broad-spectrum serine protease inhibitor which inhibits all complement proteases. In 
concordance with previous results (19), the time course of C3 deposition shows an initial lag 
phase (5-6 min) followed by a rapid amplification phase (Fig. 4). SGMI-1 reduced C3 
deposition at any phase of the AP activation. Even in the presence of surface-deposited C3b, 
SGMI-1 attenuated additional deposition of C3b, though not as efficiently as the broad-
spectrum serine protease inhibitor FUT-175. These results suggest that MASP-1 is necessary 
for maintaining an efficient amplification process of LPS-induced AP activation. However, it 
does not necessarily preclude that it is also important for the initiation.   
MASP-1 does not cleave FB 
We have assessed the direct proteolytic action of MASP-1 on components of the AP. 
Previously we studied the ability of MASP-1 to cleave C3 and pro-FD (5, 20). Here we 
checked whether MASP-1 can cleave FB. We mixed FB with C3b and rMASP-1cf, incubated 
the mixture at 37 °C and followed the digestion on SDS-PAGE (Fig. 5). We found that 50 nM 
MASP-1 was not able to cleave C3b-bound FB. Although after 1.5h some Bb fragment 
appeared, but the band was not significantly stronger than in the case of the negative control. 
Under similar conditions 0.25 nM FD cleaved FB with high efficiency. We also demonstrated 
that SGMI-1 does not inhibit FD-mediated FB cleavage significantly (Fig. 5). Taken together, 
it seems unlikely that MASP-1 exerts its proteolytic effect directly on the known components 
of the AP. Instead, it may cleave a still unidentified factor and thereby promote AP activation. 
Concluding remarks 
Our observations are in accordance with previous results from the literature. The finding that 
the mechanism of AP activation depends on the nature of the activator was reported by 
Kimura et al (21). They found that properdin was indispensable for LPS-induced AP 
activation in mouse serum whereas properdin deficiency impaired only minimally the 
zymosan-induced AP activation. The reason for the differential requirement of properdin by 
different AP activators is unknown but it is intriguing that we got the same surface-
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dependence for MASP-1-supported AP activation using NHS. It is plausible to assume that 
the extent of AP activation on certain surfaces depends on the balance between properdin- and 
MASP-1-mediated promotion and FH-dependent inhibition. It is very likely that FH binds to 
LPS more strongly than to zymosan. It is possible that there is a connection between the 
requirement of properdin and MASP-1 for the activity of the AP on certain activation 
surfaces, but further experiments are needed to investigate this possibility.  
Although anti-LPS antibodies may play a role in AP activation, removal of antibodies from 
the serum did not influence the MASP-1 dependence of LPS-induced AP activation (data not 
shown). 
Selander et al. (17) studied the contribution of MBL to AP activation. Although they 
concluded that MBL alone (without the contribution of MASPs) triggers C3 deposition on 
solid-phase mannan or mannan-rich LPS in C2 deficient serum, their experimental data 
clearly indicated that MASP-1 has a role in the C2-bypass activation. In their experiments 
serum fractions containing MBL/MASP-1 complexes were able to activate C3 in the absence 
of C2, while other MBL/MASP complexes failed to do so. The extent of the C3 deposition 
depended solely on the MASP-1 content of the MBL/MASP complexes.  We also observed 
vigorous C3 deposition on mannan-coated surface in the presence of Mg2+-EGTA, which was 
entirely MASP-1 dependent. MBL cannot bind to mannan under these conditions; however 
other PRMs may retain this ability in the absence of Ca2+ (22). It is possible that in the 
presence of Ca2+, where MBL binds to its target, the AP promoting activity of PRM-MASP-1 
complexes are even higher and may significantly contribute to the defense against Gram-
negative bacteria. Selander et al. (17) speculate that MASP-1 may act on C3 indirectly by 
recruiting other serum proteases that cleave C3. Our results are also reconcilable with this 
hypothesis especially, as we demonstrated earlier, that MASP-1 is an atypical complement 
serine protease with relatively broad substrate specificity (23). 
The fact, that MASP-1 is necessary for LPS-induced AP activation, but not for zymosan-
induced one, suggests that the mechanism of AP activation differs in the case of the two 
different activators. Further studies are required to clarify the exact molecular mechanism of 
complement activation on these activator surfaces.  
In conclusion, we discovered a novel role of MASP-1 in complement activation. Although it 
was suggested earlier by several authors that MASP-1 might contribute to AP activation, no 
solid evidence has been presented. The activator-specific requirement of MASP-1 in AP 
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activation indicates a tight interaction between the complement activation routes, which were 
previously considered independent. 
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Figure 1. Effect of inhibition of MASPs on LPS- and zymosan-induced AP complement 
activation. 
The AP activation on different activation surfaces was followed by the detection of C3 
deposition. The experiments were performed using 6-fold diluted NHS in Mg2+-EGTA buffer. 
The plates were coated with bacterial LPS (S. typhimurium) or zymosan (S. cerevisiae) and 
incubated with the serum containing different inhibitors. The MASP-1-specific inhibitor 
(SGMI-1) completely inhibited AP activation on LPS-coated surface (A), whereas the MASP-
2-specific (B) and the MASP-3-specific inhibitors (C) showed little or no effect. C3b 
deposition reflects deposition of various C3 fragments both here and in the subsequent 
figures. Results are representative of at least three independent experiments. 
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Figure 2. MASP-1 inhibitors having different mechanism of action inhibit LPS-induced AP 
activation. 
 (A) Polyclonal antibody raised against the serine protease domain of MASP-1 (αM1-SP) 
inhibited LPS-induced AP activation. (B) The N-terminal fragment of MASP-1 (M1_D1-3) 
inhibited AP activation in a concentration dependent manner on LPS-coated surface. (C) The 
serpin domain of C1 inhibitor (C1 inh) showed concentration dependent inhibitory effect on 
LPS-induced AP activation, while the full-length C1 inhibitor molecule had no effect. The AP 
activation was followed by the detection of C3 deposition. Results are representative of at 
least three independent experiments. (D) Summarizing the effects of different inhibitors on 
the AP activation on LPS- and zymosan-coated surfaces. The inhibitors were applied in the 
following concentrations: 20 µM SGMI-1, 20 µM SGMI-2, 30 µM TFMI-3, 133 nM αM1-SP, 
7.3 µM M1_D1-3, 9.1 µM C1 inhibitor serpin domain, 11.3 µM C1 inhibitor. The results 
shown are the mean ± SD of at least three independent experiments. Student’s t-test was used 
to test significant differences between NHS and treated groups; * = p<0.05; **=p<5x10-9. 
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Figure 3. C3 deposition in the presence of MASP-1-depleted serum and C3 deposition on 
different surfaces 
(A) MASP-1 depletion severely reduced C3 deposition in the case of LPS-induced AP 
activation while it had only limited effect on zymosan-induced AP activation. MASP-1-
depleted serum was applied on LPS and zymosan-coated surface. Results are representative of 
at least three independent experiments. (B) Inhibition of MASP-1 proteolytic activity blocks 
the AP activation on different surfaces. The inhibitory effect of SGMI-1 (20 µM) was tested 
on AP activation triggered by various activation surfaces. The microtiter wells were coated by 
bacterial LPS isolated from different strains (S. typhimurium, E. coli, P. aeruginosa). SGMI-1 
effectively blocked AP activation in all cases. The AP activation induced by mannan was also 
inhibited by SGMI-1. Results are representative of at least three independent experiments. 
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Figure 4. Inhibition of MASP-1 attenuates the amplification phase of LPS-induced AP 
activation. 
6-fold diluted NHS (in Mg2+-EGTA buffer) was transferred onto LPS-coated wells, incubated 
at 37 °C, and at different time points MASP-1-specific inhibitor (SGMI-1; 20 µM), or broad 
specificity serine protease inhibitor (FUT-175; 100 µM) or buffer was added and C3 
deposition was measured. SGMI-1 and FUT-175 prevented further C3 deposition even when 
the surface was partially covered with C3b. Results are representative of at least three 
independent experiments. 
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Figure 5. The effect of MASP-1 and SGMI-1 on the cleavage of C3b-bound factor B. 
C3b (1.23 µM) was mixed with FB (1.07 µM), and the resulting pro-convertase complex was 
incubated with rMASP-1cf (50 nM), or with FD (0.25 nM) in the presence or absence of 
SGMI-1 (20.5 µM). After incubation at 37 °C for 1,5 hours, the reactions were stopped, and 
the cleavage of FB was analyzed on reducing 10% SDS-PAGE. rMASP-1cf was unable to 
cleave FB, while under the same condition, FD was very efficient. FD mediated FB cleavage 
could not be significantly prevented by SGMI-1. 
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Supplementary Figure 1. Polyclonal anti-MASP-1 antibody inhibits LP activation 
Polyclonal antibody raised against the serine protease domain of MASP-1 (αM1-SP) 
efficiently inhibited lectin pathway activation, similarly to SGMI-1, while the control rabbit 
IgG did not affect LP activation. The LP activation was followed by detecting C3 deposition. 
Results are representative of at least three independent experiments. 
 
